Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $120.
September 13, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical's stock rating has been reiterated as Overweight by Cantor Fitzgerald, with a maintained price target of $120.
The reiteration of an Overweight rating by a reputable analyst like Olivia Brayer from Cantor Fitzgerald is a positive signal for Biomarin Pharmaceutical. It suggests that the analyst believes the company's stock will outperform its industry peers in the near future. The maintained price target of $120 also indicates that the analyst sees potential for the stock's price to increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100